Cancer drug developer Cell Therapeutics (CTIC) - Get Report was down 6.4% in preopen Island trading after posting a third-quarter loss of 64 cents a share, wider than analysts' expectations of 51 cents.

The company blamed weaker demand in July and August for its leukemia treatment Trisenox and higher research and development expenses.